The biotech is getting into the cannabinoids business.
News & Analysis: Intrexon
A big deal with a medical cannabis company provided a spark for Intrexon.
Investors weren't happy to learn about its worsening cash position.
The company got welcome support from a big money manager.
The company's burning through cash, and that has investors nervous.
Plants aren't always the perfect medium for producing high-value compounds. Turns out, cannabinoids can be brewed with microbes instead.
XON earnings call for the period ending December 31, 2018.
There's a new cannabis player that demands your attention.
Intrexon wants to make it easier for companies to create products that are high in cannabinoids.
Intrexon's potential entry into the cannabis industry generated enthusiasm among investors.